Introduction
Mantle cell lymphoma (MCL) is an aggressive and incurable malignant lymphoma, representing approximately 5% of non Hodgkin lymphomas with a median survival of 3 to 5 years. Despite new chemotherapeutic combinations, MCL is characterized by a poor overall response due to the rapid relapse after initial treatment or primary resistance to conventional drugs. 1 However, phase II studies are currently evaluating the efficacy of the proteasome inhibitor Bortezomib in MCL with encouraging results in relapsed and refractory cases. 2 MCL was initially depicted as a proliferative pool of pre-germinal centre (GC) naïve B cells with germline immunoglobulin heavy chain variable-region (IGHV) genes. However, numerous studies showed that about 20-30% MCL carry somatic mutations in their IGHV genes. 3 By analogy with pre-GC and post-GC cells, a subset of MCL might derive from B cell exposed to the GC environment, thus reflecting a molecular heterogeneity of MCL.
Gene profiling studies in MCL cells have revealed an overexpression of oncogenic factors such as c-Myc as well as a simultaneous deregulation of multiple genes implicated in the regulation of nuclear factor kappa B (NF-κΒ). 4 Furthermore, previous immunochemistry studies have shown that the oncogenic transcription factor signal transducer and activator of transcription 3 (STAT3) is constitutively phosphorylated on tyrosine residue in 20/43 (47%) lymph node biopsies. 5 Constitutively active STAT3 contributes to the malignant phenotype in numerous human cancer cell lines and primary tumours by promoting uncontrolled cell growth and survival through dysregulated protein expression, including interleukin-10 (IL10) and STAT3 itself. 6 Moreover, STAT3 induces tumour angiogenesis by upregulating the expression of vascular endothelial growth factor, and modulates immune functions towards tumour immune evasion. 6, 7 Overall, several studies point to STAT3 as a promising target for anticancer therapy. 8 STAT proteins are usually phosphorylated on tyrosine 705 by Janusassociated kinases (JAK) upon cytokine receptor engagement. Both IL6 and IL10 are known to phosphorylate STAT3. It has also been evidenced that MCL molecular signature included 4 overexpression of IL10 receptor 4 and that IL10 was able to sustain cell proliferation in MCL primary cells 9 , suggesting an autocrine/paracrine role for IL10 in MCL cell survival or proliferation. Activation of STAT3 in B-cells may also result from B-cell receptor (BCR) with two possible pathways: a delayed and indirect phosphorylation of STAT3 10, 11 or alternatively a JAK-independent rapid and transient phosphorylation of STAT3 by Lyn. 12 After BCR engagement, human circulating normal CD5-positive B-cells produce more IL10
than CD5-negative B-cells 13 , and in animal models a strong BCR signal is responsible for the specific expansion of CD5-positive B-cells. 14 In our study, we deciphered the signals generated by cytokines and BCR engagement resulting in STAT3 phosphorylation and subsequent MCL cell survival. We report that constitutive and/or BCR-induced STAT3 phosphorylation in primary MCL cells contribute to increased survival potential, which are both abrogated by bortezomib. were cultured during 24 hours in complete RPMI 1640 medium supplemented with 10% heatinactivated foetal calf serum. MCL cell lines were maintained in culture in the same media.
Design and Methods

MCL samples and cell lines
Normal B-lymphocytes were purified from a pool of PBMC from healthy individuals. For BCR stimulation, plates were coated with rabbit anti-human IgM antibody (10 µg/mL; Jackson ImmunoResearch, Baltimore, MD) as previously described. 15 Anti-cytokine and anti-6 cytokine receptor antibodies were purchased from R&D systems (Minneapolis USA).
Fludarabine was from Bayer Schering Pharma (Loos, France), bortezomib from Janssen-Cilag (Beerse, Belgium), Stattic and AG490 from Merck KGaA, (Darmstadt, Germany).
Determination of IGHV mutational status.
Following amplification with consensus 5' FR1c and 3' JH primers, PCR fragments were sequenced and analyzed for the mutational status using the IMGT database. Amplification and sequence analysis of IGHV rearrangements were performed on either DNA or cDNA as previously described. 16 A homology cut off value of 98% to the germline sequence was used to discriminate between unmutated (≥98%) and mutated (<98%) IGHV gene status. Both
Jeko-1 and Rec-1 cell lines exhibit unmutated IGHV gene (IGHV2-70; 99.6% homology and IGHV1-2; 98.5% homology, respectively) and HBL-2 cell line displays mutated IGHV gene (IGHV3-11, 97.4% homology).
Apoptosis and cell viability assays
Cell apoptosis was analyzed on a Coulter EPICS XL (Beckman Coulter, Villepinte, France)
by Annexin V-FITC and propidium iodide staining (BD Biosciences, San Jose, CA).
Percentage of apoptotic cells corresponded to % of annexin V-positive, including PI-negative and PI-positive cells. All measurements were done in duplicate. 
Statistical analyses.
Differences between groups were determined using the unpaired Student t test or the Wilcoxon-signed rank test as appropriate. Statistical analyses were performed using GraphPad Prism software (San Diego, CA). P values below 0.05 were considered statistically significant.
Results
The constitutive phosphorylation of STAT3 in MCL cells is dependent on a cytokine autocrine secretion.
A constitutive Tyr705-phosphorylation of STAT3 was detected by western blotting in MCL cell line Jeko-1 ( Figure 1A ). Therefore we investigated whether this constitutive phosphorylation of STAT3, as observed in MCL tumours 5 
Bortezomib inhibits constitutive activation of STAT3
Bortezomib (PS-341, Velcade) is a proteasome inhibitor currently in use for the treatment of MCL. 18, 19 We thus considered the impact of bortezomib on STAT3 phosphorylation and MCL cell survival. In vitro treatment of MCL cells with bortezomib (10 nM) induced variable but significant increase of apoptosis (mean increase in apoptosis=45%, n=14, P=0.001) ( Figure   5A ) but also abolished constitutive phosphorylation of STAT3 ( Figure 5B ) and decreased IL10 and IL6 secretion to variable extents (n=8, P < 0.01) ( Figure 5C ). Moreover, exogenous addition of IL10 overcame bortezomib-mediated blockade of STAT3 phosphorylation (supplementary Figure S4) . These results were compared to in vitro exposure to fludarabine another therapeutic agent in MCL known to interfere with p53-dependent apoptosis pathway. 20 Even exposed to high concentration of fludarabine (20 µM), MCL cells showed stronger resistance to apoptosis compared to bortezomib (mean increase in apoptosis=19%, n=14, P=0.002), and phosphorylation of STAT3 was sustained ( Figure 5 A-B). Since bortezomib was previously shown to inhibit constitutive activation of NF-κΒ in MCL 21 and that IL6 and IL10 are target genes of NF-κΒ 22 , our results were in line with a possible NF-κΒ-dependent phosphorylation of STAT3. To assess the specific impact of NF-κΒ on STAT3 phosphorylation, we used the BAY 11-7082 specific inhibitor of IκBα phosphorylation. As shown in figure 5D , BAY 11-7082 inhibited altogether the constitutive STAT3 phosphorylation, IL6 and IL10 secretion and induced cell apoptosis. Altogether, these data indicate that inhibition of STAT3 constitutive phosphorylation by bortezomib may occur through a disruption of the autocrine secretion loop of IL6/IL10. They also suggest a link between NF-κΒ and STAT3 that are both constitutively activated in MCL cells.
Bortezomib inhibits BCR-induced survival signal and BCR-induced STAT3
phosphorylation.
Bortezomib-induced in vitro apoptosis was further analyzed in the context of BCR stimulation. Bortezomib treatment significantly abrogated the BCR-induced survival response in all cases (n=14, P < 0.001) ( Figure 6A ). Meanwhile, BCR-induced phosphorylation of STAT3 was decreased or abolished after bortezomib treatment whereas it was unchanged upon fludarabine treatment ( Figure 6B ). BCR-induced STAT3 phosphorylation was also abrogated in the presence of BAY 11-7082, supporting the existence of a link between NF-κB and STAT3 pathways in the context of BCR stimulation (supplementary Figure S5) .
Discussion
The present study is focussed on the exploration of pathways, emanating from the microenvironment (antigen, cytokines) and contributing to MCL cell survival and chemoresistance, in particular through STAT3 activation. This study, performed on fresh primary MCL samples, allowed to evidence that 70% ( head and neck squamous cell carcinoma. 24 Furthermore, bortezomib-induced apoptosis of MCL cells is associated with a decrease of IL6/IL10 secretion and with an inhibition of the constitutive phosphorylation of STAT3. Given that bortezomib is also able to inhibit NF-κΒ in MCL 21 but does not affect STAT3 expression and DNA binding activity 25 , our results suggest that in MCL bortezomib-induced suppression of STAT3 phosphorylation may occur through disruption of the NF-κB-dependent cytokine autocrine loop. They also suggest that NF-κΒ and STAT3 pathways may cooperate to play an important role in MCL proliferation, as described in diffuse large B cell lymphoma. 22 Some studies have identified IGHV mutational status as a relevant prognosis factor in MCL 3, [26] [27] [28] , suggesting an involvement of antigen stimulation in the course of the disease. In these studies, cases with mutated IGHV appeared to have a better clinical outcome. 26 In the present study, all the IGHV mutated cases were associated with a constitutive phosphorylation of STAT3 whereas all cases with basal unphosphorylated STAT3 bore unmutated IGHV. Examination of the pattern of IGHV rearrangements and mutational status found in our series revealed an absence IGHV3-21 rearrangement and a high proportion of IGHV mutated cases (55%) when compared to studies carried out on biopsies. 29 This pattern appears to be characteristic of MCL leukemic presentations and corroborates with previous reports indicating that IGHV mutated cases are more frequent in non nodal than in nodal series (56% and 10% respectively) and that IGHV3-21 rearrangement, associated with unmutated IGHV are mostly described in nodal MCL 27, 30, 31 . Interestingly, all the IGHV3-21
cases we collected as well as some other unmutated IGHV cases have not been used in this functional study, and though were not included in our series, due to either a low lymphoma circulating cell count or a major rate of spontaneous apoptosis. Altogether, these results suggest that the constitutive STAT3 phosphorylation observed in MCL cases harbouring mutated IGHV and a leukemic phase may confer to malignant cells an intrinsic survival potential.
Given that BCR engagement can promote B-cell proliferation and survival, 32 we investigated its effect in both unmutated and mutated IGHV MCL cases. First, we observed IL10 treatment induced STAT3 phosphorylation in MCL cell lines lacking basal STAT3 phosphorylation. Rec-1 cells and HBL-2 cells were incubated for 24h in the absence (-) or in the presence of IL10 (50 ng/ml, R&D Systems). P-STAT3 and total STAT3 expression were analyzed by western-blotting as described in Design and Methods.
Constitutive phosphorylation of JAK3 but not JAK1 and JAK2 was detected in Jeko-1 cells and treatment with AG490 reduced phosphorylation of Jak3. Jeko-1 cells were treated for 24h with increasing concentrations of AG490 or left untreated. Cells were lysed in ice-cold 1% Nonidet P-40 (NP-40) lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 10% glycerol, and 1 mM EDTA) containing phosphatase and protease inhibitors for 30 minutes on ice. Insoluble material was removed by centrifugation at 27 000g and total cell lysates (500 µg) were immunoprecipitated (IP) with anti-Jak antibodies (anti-Jak1 and anti-Jak2 from Millipore; anti-Jak3 from Santa Cruz Biotechnology) before immunoblotting (IB) with antipTyr 4G10 antibody (Millipore). The blot was then stripped and rebloted with the corresponding anti-Jak antibodies. For IP Jak3, input extracts were also immunoblotted with α-tubulin as a control to equivalent protein amounts for immunoprecipitation. Control IP Jak1: IL4-stimulated Ramos human lymphoblastoid cell line. Control IP Jak2: Erythropoietin-stimulated UT7 human megakaryocytic cell line.
Exogenous addition of IL-10 overcomes bortezomib-mediated blockade of STAT3 phosphorylation. Primary MCL cells (UPN 3, UPN 12) were treated for 20 hours in the absence (-) or in the presence of either bortezomib (Borte, 10 nM) or IL-10 (50ng/ml, R&D systems) or bortezomib and IL-10 (Borte + IL10). P-STAT3 and total STAT3 expression were analyzed by western-blotting as described in Design and Methods.
The inhibition of NF-kB suppresses both constitutive and BCR-induced STAT3 phosphorylation. Primary MCL cells (UPN1, UPN5) were treated (+) or not (-) for 24 hours with Bay 11-7082 (4µM, Sigma) an inhibitor of NF-kB. Cells were simultaneously activated (+) or not (-) with immobilized anti-IgM. P-STAT3 and total STAT3 expression were analyzed by western-blotting as described in Design and Methods.
